1. Home
  2. CRNX vs ROMA Comparison

CRNX vs ROMA Comparison

Compare CRNX & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$33.65

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$6.30

Market Cap

134.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
ROMA
Founded
2008
2018
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
134.6M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
CRNX
ROMA
Price
$33.65
$6.30
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$74.78
N/A
AVG Volume (30 Days)
1.0M
679.8K
Earning Date
05-07-2026
12-23-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$722.66
N/A
Revenue Next Year
$183.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.10
$0.72
52 Week High
$57.99
$11.77

Technical Indicators

Market Signals
Indicator
CRNX
ROMA
Relative Strength Index (RSI) 29.20 55.28
Support Level $33.23 $2.05
Resistance Level $37.23 $8.73
Average True Range (ATR) 1.62 1.89
MACD 0.13 0.25
Stochastic Oscillator 8.33 37.20

Price Performance

Historical Comparison
CRNX
ROMA

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

Share on Social Networks: